Keytruda is set to lose exclusivity in 2028, meaning Summit may face competition from cheaper biosimilars. Meanwhile, other ...

Immutep believes its LAG-3 candidate eftilagimod alpha may have a path to approval in first-line head and neck cancer after ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

Cancer specialists and patients have welcomed news that three potentially life-saving skin cancer medicines are to be funded.

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck ...

Even when equities are volatile, investors can find great stocks to buy. And the rules for investing in the current ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

New Jersey-based pharmaceutical giant Merck is investing $1 billion in what company executives described as a continued ...